SPARK Biopharma presented in the first session "Landscape of Immuno-Oncology Drug Development"in Bio Korea 2022 organized by Korea Drug Development Fund (KDDF; 국가신약 개발 사업단) which is the biggest government fund for drug development in Korea. 

Seung Bum Park CEO introduced the UPPRIS technology to upregulate target protein by inhibiting specific interaction between target protein and E3 ligase.